Introduction: The Evolving Landscape of Pediatric Hodgkin Lymphoma
Pediatric Hodgkin lymphoma (HL) stands as one of the major success stories in modern oncology, boasting cure rates that frequently exceed 90%. However, this success has historically come at a significant cost. Survivors of pediatric HL face a lifelong risk of late-treatment toxicities, including secondary malignancies, cardiovascular disease, and endocrine dysfunctions. Many of these late effects are directly attributable to the use of ionizing radiation therapy (RT), particularly when administered to the chest or neck in young, developing patients.
In recent decades, the primary goal of clinical trials in low-risk pediatric HL has shifted from merely achieving a cure to maintaining high efficacy while minimizing long-term morbidity. The Pediatric Hodgkin Consortium (PHC) recently published the results of the HOD08 study, a phase 2 trial that investigated whether increasing chemotherapeutic dose density could increase complete response (CR) rates and, consequently, allow for the safe elimination of RT in a larger proportion of patients.
